© 2022 MJH Life Sciences™ and Urology Times. All rights reserved.
Focal therapy vs. surveillance for low-risk PCa
Urology Times asked Scott Eggener, MD: How should urologists decide between focal therapy and active surveillance in men with low-risk prostate cancer?
Urology Times asked Scott Eggener, MD: How should urologists decide between focal therapy and active surveillance in men with low-risk prostate cancer? UT spoke with Dr. Eggener at the 2019 annual meeting in Chicago.
